Trastuzumab Deruxtecan May Fulfill Unmet Need in HER2-Overexpressing NSCLC
Trastuzumab deruxtecan demonstrated activity in a phase 2 trial of patients with HER2-overexpressing, relapsed/refractory, unresectable and/or metastatic NSCLC.
Trastuzumab deruxtecan demonstrated activity in a phase 2 trial of patients with HER2-overexpressing, relapsed/refractory, unresectable and/or metastatic NSCLC.
Researchers sought to develop and implement a web-based tool to enhance involvement, communication, and shared decision making among clinicians, patients with cancer, and their caregivers.
The NCI SBIR Innovation Lab podcast reaches and engages with entrepreneurs of all levels to share insights on commercialization and success stories from biotech industry…
Biennial screening mammography is recommended for those who are 40 to 74 years old rather than individualizing screening decisions in this age group.
Cancer Research | 84 | 9 | May 2024
Cancer Prevention Research | 17 | 5 | May 2024
As immunotherapy makes its way into the perioperative setting, a growing number of clinical trials are expanding the evidence base for resectable non-small cell lung…
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
People with cancer have an increased risk of dying from COVID-19, according to 2 large studies from the United States and the United Kingdom.
The implementation of a nurse navigator in a lymphedema program has helped patients with the condition obtain timely care, which can potentially improve outcomes.
Blood | 143 | 18 | May 2024